Navigation Links
Favrille to Present at BIO InvestorForum
Date:10/2/2007

Live Webcast from the Palace Hotel in San Francisco on Wednesday, October

10th

SAN DIEGO, Oct. 2 /PRNewswire-FirstCall/ -- Favrille, Inc. (Nasdaq: FVRL), a biopharmaceutical company developing patient-specific, active immunotherapies for the treatment of cancer, today announced that Tamara Seymour, Chief Financial Officer, will present at the Biotechnology Industry Organization (BIO) InvestorForum at 10:15 a.m. Pacific time on Wednesday, October 10, 2007. The conference will be held at the Palace Hotel in San Francisco.

(Logo: http://www.newscom.com/cgi-bin/prnh/20031013/LAM095LOGO)

Ms. Seymour will provide an overview of Favrille and the clinical trials of its lead compound, FavId(R), which is currently in a pivotal Phase 3 clinical trial for the treatment of follicular B-cell non-Hodgkin's lymphoma (NHL). A live webcast of the presentation can be accessed at http://www.favrille.com. The replay will be available approximately one hour after the presentation and will be archived until November 10, 2007.

About Favrille, Inc.

Favrille, Inc. is a biopharmaceutical company focused on the development and commercialization of targeted immunotherapies for the treatment of cancer and other diseases of the immune system. The Company's lead product candidate, FavId, is based upon unique genetic information extracted from a patient's tumor. FavId is currently under investigation in a pivotal Phase 3 clinical trial for patients with follicular B-cell NHL and Phase 2 clinical trials in other B-cell NHL indications. The Company is developing additional applications based on its immunotherapy expertise and proprietary cost-effective manufacturing technology, including a second product candidate, FAV-201, for the treatment of cutaneous T-cell lymphoma.


'/>"/>
SOURCE Favrille, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Amplification of genome-representative DNA from limited sources with GenomePlex WGA technology for use in genetic alterations studies
2. Wisconsin firms to present at Cleantech venture capital event
3. New Sonic Foundry search engine finds words, phrases in video presentations
4. Lone Wisconsin firm to present at InvestMidwest
5. Sonic Foundry creates search engine for 7,000 expert video presentations
6. InvestMidWest calls for business presentations
7. Wicab to present BrainPort at Boston conference
8. Three more Wisconsin firms to present at venture forum
9. Six Wisconsin firms to present at BIO Mid-America VentureForum
10. New Health and Human Services representative for Midwest
11. Top 20 big pharmas represent majority of world pharma market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/27/2015)... CHICAGO and FRANKLIN, Tenn. ... Inc. ("Capella"), a privately-owned  premier provider of health care ... companies in the U.S., today announced that its ... has signed a definitive agreement with Medical Properties ... the acquisition of Capella for $900 million in cash.  The ...
(Date:7/27/2015)... ... 27, 2015 , ... This is a professional and in-depth ... overview of the industry including definitions, classifications, applications and industry chain structure. The ... landscape analysis, and key regions development status. Development policies and plans are discussed ...
(Date:7/27/2015)... Wis. (PRWEB) , ... July 27, 2015 , ... ... and facility identification solutions, today announced a new video: 3 Ways to ... OSHA’s Hazard Communication Standard and the Globally Harmonized System (GHS) by effectively labeling ...
(Date:7/27/2015)... Research presented at the 2015 AACC Annual ... studies that led to a fingerprick Ebola test becoming ... to receive approval from the World Health Organization (WHO). ... on West Africa by identifying ... to isolate and treat these patients much faster than ...
Breaking Biology Technology:Capella Healthcare Announces Agreement With Medical Properties Trust, Inc. 2Capella Healthcare Announces Agreement With Medical Properties Trust, Inc. 3Capella Healthcare Announces Agreement With Medical Properties Trust, Inc. 4Capella Healthcare Announces Agreement With Medical Properties Trust, Inc. 52015 Biophotonics Market Global Research 22015 Biophotonics Market Global Research 3Brady Releases “3 Roads to GHS Labels” Video 2Rapid Ebola Test Could Play Key Role in Efforts to End Lingering Outbreak 2Rapid Ebola Test Could Play Key Role in Efforts to End Lingering Outbreak 3
... intense scrutiny that started in September when Vioxxs manufacturer ... concerns, the U.S. Food and Drug Administration and the ... the biggest challenges has been the pipeline problem, the ... innovative medical therapies reaching patients. In its March ...
... Much of Thursday's Digital Healthcare Conference in ... of them. , ,In today's issue, the first of ... Digital Healthcare Conference, you'll read about the technology choices ... those choices. Next issue, look for coverage of the ...
... While Wisconsin may be ahead of the ... way to go before full use of electronic health ... the recognized quality improvements and long-term cost savings, implementation ... the Internet Business Solutions Group Healthcare Practice ...
Cached Biology Technology:Challenging times for FDA and drug companies equals IT opportunities 2Challenging times for FDA and drug companies equals IT opportunities 3The tough choices facing health care 2The tough choices facing health care 3Organizations finding ways to overcome barriers to electronic health records implementation 2Organizations finding ways to overcome barriers to electronic health records implementation 3Organizations finding ways to overcome barriers to electronic health records implementation 4
(Date:7/2/2015)... 2015 Fingerprint Cards has received an ... FPC1155 from the distributor World Peace Industrial Group (WPI), part ... Asia . Deliveries are planned to take ... used by smartphone manufacturers in Asia . ... communicated revenue guidance of approximately 2,200 MSEK for 2015. ...
(Date:6/26/2015)... 26, 2015 ATL Technology, LLC, a top provider ... in single use solutions, headquartered in Springville, Utah ... California corporation with locations in ... Jose, Costa Rica ). This acquisition will ... with ATL Technology,s existing facility in Costa ...
(Date:6/24/2015)... , June 24, 2015 The biologics ... The major drivers for the market include growth of ... of new drug launches. Over the years, the number ... Between 2001 and 2010, the FDA approved 225 drug ... to WIPO, Europe accounted for ...
Breaking Biology News(10 mins):FPC Receives Order for Touch Fingerprint Sensors of 268 MSEK 2ATL Technology Announces Acquisition of MedConx, Inc. and Expanded Global Footprint 2Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 2Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 3Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 4
... premature fusion of the skull, is estimated to affect one ... physicians have used two procedures to correct the problems. One ... strip back the scalp of the infant and reshape the ... procedure required a small incision near the point of the ...
... hard to study a creature when you only catch ... one of the big stumbling blocks for marine biologists ... allowed them to peer farther across, and deeper under, ... Satellite tracking systems and acoustic sensors are giving researchers ...
... worlds sharks are disappearing. These fearsome yet charismatic fish ... now at risk of extinction as a result. New ... overfishing, and other work shows that the deeper sharks ... recover. Yet researchers are just now learning critical details ...
Cached Biology News:Craniosynostosis minimally invasive surgery holds more promise than old procedure 2Unveiling the underwater ways of the white shark 2Unveiling the underwater ways of the white shark 3New research reveals shark superhighways and hotspots 2New research reveals shark superhighways and hotspots 3New research reveals shark superhighways and hotspots 4
Peptide-affinity Purified Polyclonal Antibody to MTR...
Polyclonal Antibody to AGAP1 / Centaurin, gamma 2...
Polyclonal Antibody to PRG3...
IRF7 Immunogen: Synthetic peptide corresponding to residues E(463) G T Q R E G V S S L D S S S(477) of human IRF7. Storage: -20 C, Avoid Freeze/Thaw Cycles...
Biology Products: